StrokeCRYSTALNCT07752563
Pilot RCT of Computer-based Eye Movement Training
A study testing NeuroEyeCoach eye movement training in people with Stroke, run by Glasgow Caledonian University.
Trial summary
The goal of this study is to learn whether NeuroEyeCoach, a computer-based eye movement training programme, can help stroke survivors with visual field loss. The study will also assess whether a larger clinical trial is feasible. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke
- What is being tested?
- NeuroEyeCoach eye movement training
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 31 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- adult (>18 years)
- stroke survivor
- stroke-related homonymous VFL (minimum quadrantanopia)
- sufficient language, cognitive, and upper limb ability to participate in trial activities.
Who cannot join
- pre-existing (ie pre-stroke) registration as sight impaired (partially sighted) or severely sight impaired (blind)
- • history of seizure disorders, especially those of a photosensitive nature
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Computer-based Eye Movement Training for Stroke-related Visual Field Loss: a Pilot Randomised Controlled Trial
The goal of this study is to learn whether NeuroEyeCoach, a computer-based eye movement training programme, can help stroke survivors with visual field loss. The study will also assess whether a larger clinical trial is feasible. The main questions it aims to answer are:
- Can stroke survivors be successfully recruited, randomised and followed up in a larger trial?
- Is NeuroEyeCoach acceptable and practical to use?
- Is there early evidence that NeuroEyeCoach improves vision-related functioning and wellbeing? Researchers will compare NeuroEyeCoach plus usual care with usual care alone.
Read more
Participants will:
- Be randomly assigned to receive NeuroEyeCoach plus usual care or usual care alone
- Complete six weeks of training if allocated to NeuroEyeCoach
- Complete questionnaires and tests of vision, daily activities, quality of life, confidence and wellbeing
- Take part in follow-up assessments over six months This pilot trial will include 60 stroke survivors living with visual field loss after stroke. Findings will be used to inform the design of a larger study.
- Conditions
- Stroke
- Being tested
- NeuroEyeCoach eye movement training, Usual Care
- Keywords
- visual field loss, rehabilitation, pilot RCT, process evaluation
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NeuroEyeCoach eye movement trainingDevice
computer based eye movement training for visual field loss in stroke
Usual CareOther
Usual post-stroke care
| Study group | Role | What they receive |
|---|---|---|
| Eye movement training + usual care | Experimental | Usual post-stroke care, plus eye movement training (VISIOcoach) Receives: Device: NeuroEyeCoach eye movement training; Other: Usual Care |
| usual care | Other | Usual post-stroke care Receives: Other: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment rate
Rate of recruitment to the trial
Measured: through study completion, estimated at 15 months
Secondary outcomes (13)
Retention Rate
Rate of retention of participants in the study
Measured: through study completion, estimated at 15 months
Screening and eligibility rate
Screening and eligibility rate
Measured: Active screening period
Outcome measure completion rate
through study completion, estimated at 15 months
Measured: over data collection period
intervention adherence
adherence to recommended training regime (duration)
Measured: 6 weeks
Adverse events
any adverse eventa experienced
Measured: up to 6 weeks
Support and computer provision needs
To what extent must technical equipment or assistance be given
Measured: up to 6 weeks
NEI VFQ 25 (National Eye Institute Visual Function Questionnaire-25)
Patient-reported measure of vision-related functioning. Minimum value is 0, and maximum value is 100; higher scores mean a better outcome
Measured: baseline, 6 weeks post randomisation, 6 months post randomisation
EQ-5D 5L
Generic health related quality of life Maximum value 1.0; better scores mean a better outcome
Measured: baseline, 6 weeks post randomisation, 6 months post randomisation
IReST (International Reading Speed Test)
Reading test (words per minute)
Measured: baseline, 6 weeks post randomisation, 6 months post randomisation
Melbourne Rapid Fields
visual field test
Measured: baseline, 6 weeks post randomisation, 6 months post randomisation
Confidence after Stroke Measure
Validated questionnaire that explores self-confidence, positive attitude and social confidence Minimum score is 0 and the maximum score is 81; a higher score indicates better outcome Ref: Horne JC, Lincoln NB, Logan PA. Measurement of confidence: the development and psychometric evaluation of a stroke-specific, measure of confidence. Clin Rehabil. 2017 Nov;31(11):1529-1537. doi: 10.1177/0269215517705424. Epub 2017 May 3. PMID: 28466669; PMCID: PMC5652651.
Measured: baseline, 6 weeks post randomisation, 6 months post randomisation
Warwick-Edinburgh Mental Wellbeing Scale
Mental wellbeing questionnaire Minimum raw score is 7 and the maximum raw score is 35; higher score means a better outcome
Measured: baseline, 6 weeks post randomisation, 6 months post randomisation
health care resource use
health care resource use, covering general, stroke specific, and vision specific resources
Measured: baseline, 6 weeks post randomisation, 6 months post randomisation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2026
- Study start1 Oct 2026 (estimated)
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Glasgow Caledonian University
- Sponsor type
- University, hospital or other
- Collaborators
- National Health Service, United Kingdom
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07752563
- Sponsor's protocol ID
- HLS/LS/25/032
- Other IDs
- TCS/24/40
- Acronym
- CRYSTAL
- Status last verified
- Aug 2026
- First submitted
- 3 Dec 2025
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: We have not yet discussed and decided our IPD sharing position
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Computer-based Eye Movement Training for Stroke-related Visual Field Loss: a Pilot Randomised Controlled Trial
- ClinicalTrials.gov ID
- NCT07752563
- Acronym / sponsor ID
- CRYSTAL / HLS/LS/25/032
- Conditions
- Stroke
- Keywords
- visual field loss, rehabilitation, pilot RCT, process evaluation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Glasgow Caledonian UniversityUniversity, hospital or other
- Collaborators
- National Health Service, United Kingdom
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jul 2027 (estimated)
- First posted
- 7 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to learn whether NeuroEyeCoach, a computer-based eye movement training programme, can help stroke survivors with visual field loss. The study will also assess whether a larger clinical trial is feasible. The main questions it aims to answer are:
- Can stroke survivors be successfully recruited, randomised and followed up in a larger trial?
- Is NeuroEyeCoach acceptable and practical to use?
- Is there early evidence that NeuroEyeCoach improves vision-related functioning and wellbeing? Researchers will compare NeuroEyeCoach plus usual care with usual care alone.
Participants will:
- Be randomly assigned to receive NeuroEyeCoach plus usual care or usual care alone
- Complete six weeks of training if allocated to NeuroEyeCoach
- Complete questionnaires and tests of vision, daily activities, quality of life, confidence and wellbeing
- Take part in follow-up assessments over six months This pilot trial will include 60 stroke survivors living with visual field loss after stroke. Findings will be used to inform the design of a larger study.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Eye movement training + usual care | Experimental | Device: NeuroEyeCoach eye movement training, Other: Usual CareUsual post-stroke care, plus eye movement training (VISIOcoach) |
| usual care | Other | Other: Usual CareUsual post-stroke care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- adult (>18 years)
- stroke survivor
- stroke-related homonymous VFL (minimum quadrantanopia)
- sufficient language, cognitive, and upper limb ability to participate in trial activities.
Key exclusion criteria (2 listed)
- pre-existing (ie pre-stroke) registration as sight impaired (partially sighted) or severely sight impaired (blind)
- • history of seizure disorders, especially those of a photosensitive nature
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NeuroEyeCoach eye movement trainingcomputer based eye movement training for visual field loss in stroke | Device | Eye movement training + usual care |
| Usual CareUsual post-stroke care | Other | Eye movement training + usual care, usual care |
Primary outcome
Recruitment rate
Time frame: through study completion, estimated at 15 months
Rate of recruitment to the trial
13 secondary outcomes
Retention Rate
Time frame: through study completion, estimated at 15 months
Screening and eligibility rate
Time frame: Active screening period
Outcome measure completion rate
Time frame: over data collection period
intervention adherence
Time frame: 6 weeks
Adverse events
Time frame: up to 6 weeks
Support and computer provision needs
Time frame: up to 6 weeks
NEI VFQ 25 (National Eye Institute Visual Function Questionnaire-25)
Time frame: baseline, 6 weeks post randomisation, 6 months post randomisation
EQ-5D 5L
Time frame: baseline, 6 weeks post randomisation, 6 months post randomisation
IReST (International Reading Speed Test)
Time frame: baseline, 6 weeks post randomisation, 6 months post randomisation
Melbourne Rapid Fields
Time frame: baseline, 6 weeks post randomisation, 6 months post randomisation
Confidence after Stroke Measure
Time frame: baseline, 6 weeks post randomisation, 6 months post randomisation
Warwick-Edinburgh Mental Wellbeing Scale
Time frame: baseline, 6 weeks post randomisation, 6 months post randomisation
health care resource use
Time frame: baseline, 6 weeks post randomisation, 6 months post randomisation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Individual participant dataSharing planned: Undecided. We have not yet discussed and decided our IPD sharing position
Related trials for Stroke
Not yet recruiting
Closed-Loop SCS-BCI for Post-Stroke Hemiplegia
Stroke, Motor Dysfunction
Active, not recruiting
Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke
Stroke, Cognitive Dysfunction
Not yet recruitingObservational study
A Speaking-Valve-Based Decannulation Protocol for Tracheostomized Stroke Patients
Stroke Patients, Tracheostomy
RecruitingPhase 4
Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals
Cerebrovascular Disorders
Not yet recruiting
Effect of Early Tendon Vibrations on Upper Limb Motor Recovery After a Stroke
Acute Stroke, Upper Limb Motor Deficit
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing NeuroEyeCoach eye movement training in people with Stroke, run by Glasgow Caledonian University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christine Hazelton, PhD (0141 331 8181, christine.hazelton@gcu.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment rate (time frame: through study completion, estimated at 15 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.